Press Release
FOR IMMEDIATE RELEASE
Northern Virginia — May 5, 2025
Federal Health Policy Advisor Discovers First Path to Remission for Long COVID, ME/CFS, and 50+ Chronic Conditions — Built in 4 Months, Featuring Breakthrough Gene Editing Platform CRISPR Remission™
Contact:
Cynthia Adinig, Federal Policy Advisor & Advocate
Email: cynthia@cynaera.com
Website: www.cynaera.com
Northern Virginia, May 2025 – Cynthia Adinig, a federal policy advisor appointed under the Biden administration and a nationally recognized Long COVID advocate, has identified the first systematized path to remission for infection-associated chronic conditions, including Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS). She built the entire model in under four months after witnessing deep cuts to NIH funding and the quiet rollback of several federal initiatives, including the Office of Long COVID.
“I built it because the agencies we counted on to solve this started walking away,” said Adinig. “After watching the NIH defund key workstreams and seeing programs dissolve without warning, I realized: no one was coming. So I did it myself, and I did it in four months.”
What began as a mission to save her own life has now become a clinical platform preparing for early trial partnerships and a roadmap for tackling the conditions science has left unresolved for decades.
A Model Built in Months, Not Years
While major institutions spent years circling symptom clusters, Adinig designed a remission framework grounded in lived experience, AI-powered terrain modeling, and deep pattern recognition across complex chronic illness. Her model moved from concept to pre-pilot in under 120 days, bypassing bureaucratic timelines and centering patient survival as the innovation driver.
Her white paper, The Science of Remission, outlines the framework and its real-world application. It includes stabilization strategies, digital trial simulations, and a new CRISPR-based therapeutic model designed to finally address the biological root causes of chronic multisystem disease.
About the Discovery
The model was developed through CYNAERA, the AI-driven systems research firm Adinig founded to accelerate chronic illness innovation. Her IACC Terrain Model™ identifies four key disruptions, immune dysregulation, mitochondrial dysfunction, autonomic instability, and neuroinflammation and maps their sequence, intensity, and intervention potential across millions of patient profiles.
Complementing this, CYNAERA introduced the Composite Diagnostic Fingerprint (CDF), a validated, high-specificity diagnostic framework that integrates 12 biomarkers across immunological, neurological, cardiovascular, and metabolic systems, enhanced by digital phenotyping. This approach addresses the diagnostic challenges of Long COVID, especially in cases often misclassified or overlooked, such as pediatric patients or those with mild initial infections. By standardizing diagnosis, the CDF guides personalized treatment and ensures broader access to care.
Her most groundbreaking contribution: the invention of CRISPR Remission™, a new genomic tool that applies CRISPR not to rare inherited mutations, but to dynamic, multisystem dysfunctions caused by post-infectious damage. By targeting immune overactivation, mast cell expression, and autonomic gene signaling, CRISPR Remission™ opens a door to systemic resolution, not just symptom control.
Paired with CYNAERA’s STAIR Stable Method™ and Clinical Trial Simulator, these tools allow researchers to model and test recovery strategies digitally and safely before human trials begin.
Who Is Behind the Work
Cynthia Adinig is a federal health policy advisor, strategist, and patient advocate who played a key role in shaping bipartisan Long COVID legislation, including early contributions to the COVID-19 Long Haulers Act. She has worked directly with members of Congress across the aisle, including longstanding collaborations with Senator Tim Kaine, who also lives with Long COVID.
Adinig served as an advisor to the Mt. Sinai CORE, under Dr. David Putrino. She currently contributes to the T-cell immunology research team led by Dr. Liisa Selin at UMass Chan Medical School and is a co-author of research publications with investigators from Mt. Sinai, Yale, and the University of South Carolina, bringing scientific, immunological, and patient-centered insight to the research pipeline.
She has advised the U.S. Department of Health and Human Services, testified before Congress, and worked with national institutions on healthcare access and systems reform. She is the co-founder of the BIPOC Equity Agency, a board member at Solve ME.
“This is personal, but it’s also national. My son Aiden has Long COVID. I built this so he wouldn’t have the same experience I did.”
Why This Matters
More than 100 million people worldwide are estimated to live with infection-associated chronic conditions, including Long COVID, ME/CFS, POTS, MCAS, and chronic Lyme. In the U.S. alone, Long COVID pushed over 4 million people out of the labor force at its peak. The total economic cost is estimated at $3.7 trillion, according to the Brookings Institution.
But the cost isn’t just financial, it’s deeply biological. These immune and inflammatory breakdowns are increasingly linked to elevated cancer risk, particularly among post-viral and chronically inflamed populations. Adinig’s model doesn’t just reverse chronic illness, it may also help stabilize pre-cancerous immune terrain, offering new paths to prevention and immune recalibration.
“We’ve watched post-viral illness explode and now we’re seeing cancer follow,” said Adinig. “If we can stabilize the terrain early, we may prevent both.”
What’s Next
CYNAERA is onboarding its first pilot cohort of researchers, clinicians, and biotech partners to test the system across conditions. Tools will be available through the CYNAERA Market in Q2 2025. The company is also engaging with select collaborators to prepare CRISPR Remission™ for preclinical modeling and safety validation.
The implications of this work extend far beyond Long COVID and ME/CFS. The same immune terrain disruptions addressed by CRISPR Remission™, chronic inflammation, immune exhaustion, autonomic dysfunction, are central to cancer progression, HIV persistence, and emerging neurodegenerative diseases like MS, and Alzheimer’s. CYNAERA’s framework offers a new playbook for accelerating recovery and immune recalibration across some of the most intractable diseases of our time.
“I designed this to reverse Long COVID, but the implications go much further,” said Adinig. “We may be able to stabilize immune terrain for cancer, HIV, and even Alzheimer’s. I’m not just treating symptoms, I’m redesigning how we recover.”
To access the white paper or request partnership information, visit www.cynaera.com
Press Contact:
Cynthia Adinig
cynthia@cynaera.com